Background and Aim: To investigate the efficacy and safety of premedication with simethicone/Pronase during esophagogastroduodenoscopy (EGD) with sedation.
INTRODUCTION

C
HINA HAS A high incidence of gastric cancer. Gastric cancer accounts for 15.8% of all newly diagnosed cancer in China. In 2015, it was the second leading cause of cancer death (17.7%). 1 In comparison to Japan, a country that has a similar rate of gastric cancer, the survival rate of gastric cancer in China is significantly lower. One of the important factors that has contributed to the higher survival rate in Japan is the existence of an effective screening program which yields a high diagnostic rate for early gastric cancer. 2 This, in turn, enables doctors to proceed with endoscopic resection, and increases the 5-year survival rate to an excellent 92.2%. 3 It is sufficient to say that with such robust evidence, detecting gastric cancer in the early stage is the key factor to reducing cancer mortality. [4] [5] [6] Endoscopists can now detect early cancer with the aid of advanced imaging in endoscopy. A major technical obstacle in achieving good quality of endoscopic examination of the gastric mucosa is the presence of foam and mucus over the mucosal surface. These substances may obscure important structural abnormalities and reduce the rate of early cancer detection. For this reason, in some countries, especially in Japan, premedication with antifoam/mucus agent has become standard practice to improve visibility during esophagogastroduodenoscopy (EGD). [7] [8] [9] [10] Among the antifoam/mucus agents, simethicone and Pronase are a common combination of premedication used for endoscopy purposes.
Many patients have increased anxiety during the endoscopic procedure and this may lead to inadequate time for the endoscopist to carry out a quality endoscopic examination. Hence, sedation is widely used during gastrointestinal endoscopy to reduce pain and anxiety. 11, 12 The use of antifoam/mucus agent has raised concern of aspiration pneumonia. The volume of 50-100 mL antifoam/mucus ingested prior to the upper gastrointestinal endoscopy examination may risk the patient for aspiration especially when the intragastric pressure increases with gas insufflation. 7, 13 The risk may be even higher if the patient is sedated. Moreover, some believe that the use of antifoam/mucus is unnecessary as the deep sedation itself may decrease gastric secretion during the procedure.
There are limited studies that report on the problem of the efficacy and safety of antifoam/mucus agents in upper gastrointestinal endoscopy examination with sedation. Therefore, the aim of the present study was to evaluate such practice and attempt to resolve this debate.
METHODS
Patients
F
ROM AUGUST TO November 2016, we enrolled a consecutive series of patients, ranging in age from 15 to 70 years old, who were referred to Digestive Endoscopic Center of Beijing Friendship Hospital for EGD.
Exclusion criteria are listed below. Patient: 1 has contraindication for EGDS 2 has known allergy to the premedication 3 has life-threatening gastrointestinal disease 4 has active gastrointestinal bleeding 5 has a history of gastrointestinal surgery 6 is pregnant or breastfeeding 7 refuses to participate in this study. 
Premedication and endoscopic procedure
Patients were randomly assigned to two groups (allocation ratio was 1:1) by computer-generated random numbers before the endoscopy procedure. In the LHM group, patients received 10 mL lidocaine hydrochloride mucilage which was ingested 5 min before the endoscopy procedure. In the SP/LHM group, patients received 80 mL warm solution with 80 mg simethicone (Berlin-Chemie AG, Berlin, Germany), 1 g sodium bicarbonate and 20 000 U Pronase (Beijing Tide-Pharmaceutical Co., Ltd, Beijing, China) 20 min before the endoscopy procedure. Similarly, patients in the SP/LHM group also received 10 mL lidocaine hydrochloride mucilage to be ingested 5 min before the endoscopy procedure.
All patients were deeply sedated for EGD in the presence of a qualified anesthetist (F.K.L). Deep sedation was achieved by propofol which was given at 1.5-2.5 mg/ kg. Administration interval was 5-7 min. A slow bolus of 0.5 mg/kg propofol was added if the sedation was not deep enough. During deep sedation, patients' vital signs including pulse oximetry, heart rate, blood pressure and three-lead electrocardiogram were monitored. All patients were given oxygen supplement of 3-4 L/min by oxygen mask. Any SpO 2 lower than 90% was considered hypoxemia. In the event of hypoxemia, the anesthesiologist increased the rate of oxygen flow, aiming for SpO 2 of 94% and above.
An experienced endoscopist (W.Y.L who has a lifetime endoscopy experience of 50 000 and carries out 3000 screening EGD annually) carried out EGD for all patients. The endoscopist was blinded to the premedication used. All the EGD were done with the same model of endoscope (Olympus GIF 260; Olympus, Tokyo, Japan).
The endoscopist reported visibility scores of esophagus, gastric antrum, upper gastric body, lower gastric body and gastric fundus, respectively. Visibility scores were classified as 1-4 based on the standard classification suggested by Kuo et al. 8 and the criteria for visibility scores for each location are shown in Figure 1 . At the same time, a nurse was assigned to record the visibility scores, number of mucosal areas that needed to be cleansed with water, amount of water consumed for mucosal cleansing, time taken for mucosal inspection (i.e. excluding the time used to obtain biopsy specimens) and number of diminutive lesions (lesion ≤5 mm) detected. The nurse also recorded whether patients had a gag reflex during the procedure and oxygenation level (SpO2, continuous pulse oximetry) when the endoscope reached different locations of the upper gastrointestinal tract (gastric cardia, duodenal papilla and gastric fundus) during endoscopy.
All biopsy specimens taken during the procedure were sent to an authorized pathologist (G.Y.C), who was also blinded to the premedication used. Pathological diagnosis was made in accordance with the Chinese consensus of digestive endoscopy biopsy and pathology regulations.
Statistical analysis
Acquired data were interpreted as means AE standard deviation (SD) or numbers (%). Primary outcome was rate of detection of premalignant gastric lesion.
14 Secondary outcome was rate of hypoxemia (a surrogate marker for aspiration pneumonia). Sample-size calculation showed that 209 patients were required in each group to achieve a statistically significant difference at the level of 0.05 with a power of 80% based on data from another study. 15 Early cancer detection rate in that study was 0.06 in the test group which used simethicone/Pronase, and the control group was 0.01. Continuous variables were assessed by Student's t-test and categorical variables were tested by chi-squared test or Fisher's exact test. P < 0.05 was considered statistically significant. Statistical analysis was carried out with SPSS 24.0. 
RESULTS
Demographic characteristics of patients W E ENROLLED 615 patients into our study. Five patients were excluded in accordance with the exclusion criteria: three patients had a history of gastrointestinal surgery and two had active gastrointestinal bleeding. Patients were randomly allocated using computer-generated numbers into the LHM (314 patients) and SP/LHM groups (296 patients) (Fig. 2 ). There were no differences between the two groups in terms of age, gender and indication for endoscopy (Table 1) .
Visibility scores
Visibility scores of LHM and SP/LHM for esophagus (1.697 AE 0.487 vs 1.209 AE 0.408, P < 0.01), gastric antrum (1.427 AE 0.661 vs 1.111 AE 0.365, P < 0.01), upper gastric body (1.943 AE 0.353 vs 1.807 AE 0.404, P < 0.01), lower gastric body (1.573 AE 0.562 vs 1.159 AE 0.393, P < 0.01), gastric fundus (1.338 AE 0.537 vs 1.061 AE 0.279, P < 0.01) and total visibility score (7.978 AE 1.526 vs 6.348 AE 1.097, P < 0.01) are shown in Table 1 . SP/ LHM had a significantly lower score than LHM in terms of individual visibility score for each area and also the total visibility score, indicating better mucosal visualization. Effort required to cleanse gastric mucosa with water and time required for endoscopy examination Table 2 shows the number of areas needed to be cleansed in the esophagus and stomach, amount of water used (to cleanse the mucosa of foam and mucus) and length of time taken for the procedure. 87.6% and 98.6% of patients' esophagus and gastric region did not need to be cleansed during EGD in LHM and SP/LHM, respectively. Number of areas that needed to be cleansed and amount of water used to cleanse the mucosa were significantly less in the SP/LHM than in the LHM (P < 0.01). Length of time to complete the mucosal examination for the endoscopy procedure in the SP/ LHM group was significant longer than in the LHM group (246.331 AE 72.097 s vs 266.024 AE 76.764 s, P = 0.01).
Diminutive lesions and pathological diagnosis
Diminutive lesions were defined as lesions smaller than or equal to 5 mm. There was no significant difference between LHM and SP/LHM cohorts for the detection of polyp The endoscopist took 62 biopsies in the LHM group and 92 biopsies in the SP/LHM group, which translated to a significant difference in the biopsy rate of 19.7% and 31.1%, respectively (P = 0.001). There were more findings of atrophic gastritis (3 vs 17, P = 0.014) and intestinal metaplasia (8 vs 26, P = 0.024) diagnosed in the SP/LHM than in the LHM group (Table 3 ; Fig. 3 ). No highgrade intraepithelial neoplasia was detected in the two groups. There was also no significant difference for the detection of low-grade intraepithelial neoplasia (1 vs 8, P = 0.085) between the LHM and the SP/LHM groups.
Safety: Rate of gag reflex and hypoxemia
There was no significant difference in the presence of gag reflex in both group of patients (LHM 6.37% vs SP/LHM 7.43%, P = 0.604). We observed no significant difference in LHM vs SP/LHM in terms of patient oxygenation (measured with pulse oximetry) when the endoscope reached the gastric cardia (99.71 AE 0.75% vs 99.72 AE 0.81%, P = 0.839), duodenal papilla (98.27 AE 1.26% vs 98.22 AE 1.36%, P = 0.608), and gastric fundus (98.55 AE 1.00% vs 98.46 AE 1.01%, P = 0.282) ( Table 4) . There is a risk of aspiration when a significant volume of 50-100 mL of premedication is consumed by patients just before the procedure. Moreover, the need for such practice Figure 3 Biopsy and pathological diagnosis. Biopsy rate was 19.7% and 31.1% in the LHM and SP/LHM, groups, respectively. There was a statistically significant difference between the two groups (P = 0.001). In patients in whom biopsy was carried out during the procedure, more atrophic gastritis (P = 0.014) and intestinal metaplasia (P = 0.024) were detected in the SP/LHM group. However, there was no high-grade intraepithelial neoplasia in the two groups, and detection of low-grade intraepithelial neoplasia (P = 0.085) was not significantly different between the LHM and SP/LHM groups. , LHM, control group; , SP/LHM, intervention group.
to improve visualization is being challenged as some hold the belief that deep sedation itself is adequate to reduce gastric secretion, hence giving optimal mucosal visualization during the endoscopy examination.
In the present study, we found that premedication with simethicone/Pronase improved visualization during EGD. The practice is deemed safe as there was no significant hypoxemia in the intervention group, which was a surrogate marker for aspiration. Based on the results, we recommend premedication with simethicone/Pronase to be used in the sedation for screening EGD with the aim of improving early detection of malignant lesions.
The SP/LHM group had lower visibility score, less area to be cleansed and less water consumed for mucosal cleansing, as reported in one study. 7 Paradoxically, in the present study, the endoscopist took a significantly longer time during the procedure in the SP/LHM group than in the LHM group. In comparison to the study done by GJ Lee et al., 16 they found that the endoscopist needed less time during the procedure in the group receiving simethicone and Pronase (P < 0.05). In addition, Wang et al. 18 found that there was no difference in the length of procedural time between the control group and the experimental group. The possible explanation for the result in our study is that with improved visibility, there were more suspicious areas visualized. This, in turn, raises suspicion of the endoscopist and requires them to take a longer time to observe such findings. Besides, with an excess 80 mL solution ingested before the procedure, the endoscopist needed longer time to clear the solution with the endoscope. Although there was a significant difference in number, the clinical implication of 2 s difference in the length of time for the examination is negligible.
The ability to detect diminutive lesions, which was defined as lesions smaller than or equal to 5 mm, is vital for the diagnosis of early gastric cancer. Although there was no difference in detecting diminutive lesions in both groups of patients, more biopsies were taken during the procedure in the SP/LHM group, leading to more cases of atrophic gastritis and intestinal metaplasia being diagnosed. It is selfexplanatory that with better visibility of the gastric mucosa, accuracy of endoscopic targeted biopsy will improve. Detecting these premalignant tissues is important in planning surveillance for such patients in detecting early gastric cancer. Similar finding was noted by SY Lee et al., 19 who used a flushing technique for the application of Pronase that facilitated improvement in depth of the biopsy, anatomical orientation and overall diagnostic adequacy. More findings of atrophic gastritis and intestinal metaplasia are also very important because they are associated with early gastric cancer. 6, 20, 21 It allows patients to be recruited into the surveillance program, hence avoiding delayed diagnosis of gastric cancer. 22 There is always a concern of aspiration pneumonia during an endoscopy procedure when the patient is given premedication, especially if the patient is deeply sedated. 7, 13 As a safety precaution, our endoscopist routinely did luminal endoscopic suction and clearance of intragastric fluid as soon as the tip of the gastroscope reached the stomach cavity, as well raising the head end of the bed to prevent aspiration. These measures seemed to work as there was no significant increase of gag reflex and hypoxemia in the intervention group of this trial, which was thought to be an acceptable surrogate marker of aspiration.
There are limitations in the present study. First, although this was a single-blinded study, potential bias could arise when the endoscopist found more fluid in the intragastric cavity in patients in the SP/LHM group during EGD. We hope to reduce the bias by using a more objective visibility scoring system rather than a subjective report of visibility adequacy by the endoscopist. Second, we did not diagnose any early gastric cancer in all of the 610 patients and intraepithelial neoplasia was not significantly different between the two groups in our study. One probable explanation is that the incidence of gastric cancer is low for the population we had screened. Rate of incidence of newly diagnosed gastric cancer is about 40 per 10 000 people.
1 A possible step to improve the detection of early gastric cancer in future studies can be achieved by increasing the number of subjects in the study or including only the high-risk population group (i.e. patients with a family history of Helicobacter pylori infection or gastric cancer).
To date, there is no international agreement on premedication use for upper gastrointestinal endoscopy examination. For example, Japanese endoscopists routinely use premedication to achieve better visibility of the gastric mucosa. Contrary to that, some Western countries avoid the use of premedication because of possible increased risk of aspiration if used with sedation. 7 There is also no standard recommendation or guidelines for such practice in China. As a result of the present study, we recommend the routine use of premedication with simethicone/Pronase during EGD 
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